Detalhe da pesquisa
1.
Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.
Ann Rheum Dis
; 77(4): 488-494, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29259050
2.
Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.
Cancer Med
; 12(20): 20242-20250, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37824431
3.
Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
Arthritis Res Ther
; 21(1): 122, 2019 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31113455
4.
[Quality characteristics and non-clinical/clinical profile of Filgrastim BS injection syringe "Mochida"/"F"].
Nihon Yakurigaku Zasshi
; 142(6): 304-14, 2013 Dec.
Artigo
em Japonês
| MEDLINE | ID: mdl-24334930